Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metformin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - metformin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - metformin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - metformin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tramadol hydrochloride, quantity: 200 mg - tablet, modified release - excipient ingredients: hypromellose; hydrogenated castor oil; maize starch; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; povidone; magnesium stearate; sodium starch glycollate; colour - tramadol sandoz sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramadol sandoz sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramadol sandoz sr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tramadol hydrochloride, quantity: 150 mg - tablet, modified release - excipient ingredients: sodium starch glycollate; lactose monohydrate; colloidal anhydrous silica; maize starch; hypromellose; microcrystalline cellulose; magnesium stearate; povidone; calcium hydrogen phosphate dihydrate; hydrogenated castor oil; colour - tramadol sandoz sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramadol sandoz sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramadol sandoz sr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tramadol hydrochloride, quantity: 100 mg - tablet, modified release - excipient ingredients: hypromellose; lactose monohydrate; calcium hydrogen phosphate dihydrate; magnesium stearate; sodium starch glycollate; hydrogenated castor oil; povidone; microcrystalline cellulose; maize starch; colloidal anhydrous silica; colour - tramadol sandoz sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramadol sandoz sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramadol sandoz sr is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 5 mg - tablet, uncoated - excipient ingredients: maize starch; stearic acid; lactose; magnesium stearate; quinoline yellow aluminium lake; brilliant blue fcf aluminium lake - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. coumadin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. coumadin is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 1 mg - tablet, uncoated - excipient ingredients: stearic acid; magnesium stearate; maize starch; lactose; quinoline yellow aluminium lake; amaranth aluminium lake - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. coumadin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. coumadin is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; copovidone; magnesium stearate; hypromellose; microcrystalline cellulose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin